ESMO 2024 – Nuvalent looks beyond its late-line Alkove
Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.
Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.
The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.
Of the big oncology deals since 2016, there are still plenty that could go either way.
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.